TY - JOUR
T1 - Risk of pulmonary emboli after removal of an upper extremity central catheter associated with a deep vein thrombosis
AU - Houghton, Damon E.
AU - Billett, Henny Heisler
AU - Gaddh, Manila
AU - Onadeko, Oluwatomiloba
AU - George, Gemlyn
AU - Wang, Tzu Fei
AU - Oo, Thein H.
AU - Feng, Mingen
AU - Dasgupta, Mahua
AU - Jaglal, Michael
AU - Streiff, Michael B.
AU - Simpson, Pippa
AU - Gali, Radhika
AU - Kreuziger, Lisa Baumann
N1 - Funding Information:
The above work was performed through VENUS. Statistical support was provided through funding by Versiti.
Publisher Copyright:
© 2021 American Society of Hematology. All rights reserved.
PY - 2021/7/27
Y1 - 2021/7/27
N2 - Standard treatment of catheter-associated upper extremity deep vein thrombosis (UEDVT) is anticoagulation, although catheters are often removed for this indication. The optimal time for catheter removal and whether the act and/or timing of catheter removal is associated with pulmonary embolism (PE) remain unknown. A retrospective cohort study was performed at 8 participating institutions through the Venous thromboEmbolism Network US. Patients with hematologic malignancies and central venous catheter (CVC)-associated UE-DVT were included from 1 January 2010 through 31 December 2016. The primary outcome was objectively confirmed PE within 7 days of UE-DVT diagnosis in anticoagulated patients comparing early (≥48 hours) vs delayed (>48 hours) catheter removal. A total of 626 patients were included, among whom 480 were treated with anticoagulation. Among anticoagulated patients, 255 underwent early CVC removal, while 225 had delayed or no CVC removal; 146 patients received no anticoagulation, among whom 116 underwent CVC removal alone. PE within 7 days occurred in 2 patients (0.78%) with early removal compared with 1 patient (0.44%) with delayed or no CVC removal (P>.9). PE or any cause of death within 7 days occurred in 3 patients in both the early removal (1.18%) and delayed/no removal (1.33%) groups (P > .9). In patients treated with CVC removal only (no anticoagulation), there were no PEs but 3 deaths within 7 days. In patients with hematological malignancy and CVC-associated UE-DVT, early removal of CVCs was not associated with an increased risk of PE compared with delayed or no removal.
AB - Standard treatment of catheter-associated upper extremity deep vein thrombosis (UEDVT) is anticoagulation, although catheters are often removed for this indication. The optimal time for catheter removal and whether the act and/or timing of catheter removal is associated with pulmonary embolism (PE) remain unknown. A retrospective cohort study was performed at 8 participating institutions through the Venous thromboEmbolism Network US. Patients with hematologic malignancies and central venous catheter (CVC)-associated UE-DVT were included from 1 January 2010 through 31 December 2016. The primary outcome was objectively confirmed PE within 7 days of UE-DVT diagnosis in anticoagulated patients comparing early (≥48 hours) vs delayed (>48 hours) catheter removal. A total of 626 patients were included, among whom 480 were treated with anticoagulation. Among anticoagulated patients, 255 underwent early CVC removal, while 225 had delayed or no CVC removal; 146 patients received no anticoagulation, among whom 116 underwent CVC removal alone. PE within 7 days occurred in 2 patients (0.78%) with early removal compared with 1 patient (0.44%) with delayed or no CVC removal (P>.9). PE or any cause of death within 7 days occurred in 3 patients in both the early removal (1.18%) and delayed/no removal (1.33%) groups (P > .9). In patients treated with CVC removal only (no anticoagulation), there were no PEs but 3 deaths within 7 days. In patients with hematological malignancy and CVC-associated UE-DVT, early removal of CVCs was not associated with an increased risk of PE compared with delayed or no removal.
UR - http://www.scopus.com/inward/record.url?scp=85111232746&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85111232746&partnerID=8YFLogxK
U2 - 10.1182/bloodadvances.2021004698
DO - 10.1182/bloodadvances.2021004698
M3 - Article
C2 - 34264267
AN - SCOPUS:85111232746
SN - 2473-9529
VL - 5
SP - 2807
EP - 2812
JO - Blood Advances
JF - Blood Advances
IS - 14
ER -